Table 1.

Revised Criteria for Clinical Diagnosis of the Metabolic Syndrome.

Revised Criteria for Clinical Diagnosis of the Metabolic Syndrome
Measure	Categorical Cut Points
Elevated waist circumference *	Population- and country-specific definitions
Elevated triglycerides (drug treatment for elevated triglycerides is an alternate indicator †)	150 mg/dL (1.7 mmol/L)
Reduced HDL-C (drug treatment for reduced HDL-C is an alternate indicator †)	<40 mg/dL (1.0 mmol/L) in males; <50 mg/dL (1.3 mmol/L) in women
Elevated blood pressure (antihypertensive drug treatment in a patient with a history of hypertension is an alternate indicator)	Systolic 130 and/or diastolic 85 mm Hg
Elevated fasting glucose ‡ (drug treatment of elevated glucose is an alternate indicator)	100 mg/dL

HDL-C indicates high-density lipoprotein cholesterol. * It is recommended that the IDF cut points be used for non-Europeans and either the IDF or AHA/NHLBI cut points used for people of European origin until more data are available. † The most used drugs for elevated triglycerides and reduced HDL-C are fibrates and nicotinic acid. A patient taking 1 of these drugs can be presumed to have high triglycerides and low HDL-C. High-dose −3 fatty acids presume high triglycerides. ‡ Most patients with type 2 diabetes mellitus will have the metabolic syndrome by the proposed criteria.